New Study Unveils the Optimal Exercise Dose for Combating Hepatic Steatosis
A groundbreaking study has identified the ideal exercise regimen for reducing hepatic steatosis, a condition closely linked to metabolic dysfunction-associated steatotic liver disease (MASLD). This condition not only accelerates the progression of liver diseases like cirrhosis but also significantly increases the risk of cardiovascular issues and extrahepatic malignancies. The good news is that hepatic steatosis can be reversed in its early stages, making exercise a powerful tool in its management.
The concept of 'exercise as medicine' is well-established, and recent research has focused on understanding the impact of different exercise components on health. However, a critical gap in knowledge persists: which exercise type is most effective for reducing hepatic steatosis, and how does the dose of each type correlate with its benefits? This uncertainty hampers the ability to confidently prescribe the optimal exercise regimen.
To bridge this gap, a comprehensive systematic review, published online on January 12, 2026, in the Journal of Sport and Health Science, offers valuable insights. Conducted by researchers from China, the study, titled 'Dose-Response Relationship Between Exercise and Hepatic Steatosis: A Systematic Review with Bayesian Network Meta-Analysis of Randomized Controlled Trials,' synthesizes existing evidence on exercise interventions for hepatic steatosis reduction.
Led by Associate Professor Chunxiang Qin's team from Central South University, with Dr. Xinyun Tan as the first author from the Xiangya School of Nursing, the study addresses three key questions: (1) Which exercise type is most effective for reducing hepatic steatosis? (2) What is the optimal dose for maximum benefit? (3) What is the minimum dose required to achieve a clinically significant difference?
The authors conducted an extensive literature search across 12 databases, including PubMed, Web of Science, and Embase, screening 1,892 records published until May 27, 2025. They included 24 studies in the analysis, ensuring a rigorous and unbiased approach.
The findings reveal a nonlinear relationship between exercise dose and hepatic steatosis. Initially, as exercise intensity increases, hepatic benefits also rise. A dose exceeding 460 MET-min/week achieves the minimal clinical difference, while benefits plateau when the dose exceeds 630 MET-min/week. The maximum benefit is achieved at 850 MET-min/week. Interestingly, this dose-response relationship varies by exercise type, possibly due to the distinct mechanisms by which different exercises reduce hepatic steatosis.
Engaging in a combination of aerobic and resistance exercise exceeding 130 MET-min/week is sufficient to produce clinically meaningful hepatic improvements. This finding highlights the therapeutic and dosage advantages of combining aerobic and resistance exercises.
The study also supports the 'Extreme Exercise Hypothesis,' suggesting the existence of minimum and maximum safe doses for generating hepatic benefits. Additionally, the efficacy of exercise in reducing hepatic steatosis may be influenced by individual factors such as disease status, medication use, and intervention duration. Therefore, personalized exercise prescriptions are recommended to optimize outcomes.
Dr. Tan emphasizes the need for future research to validate the interaction between exercise dose and type through clinical trials and to develop personalized exercise prescriptions. This will enable the refinement of exercise interventions into precise, personalized tools, ultimately enhancing individual exercise outcomes and the overall role of exercise in population health.
